Although Tau showed a negative effect in AD, PD, and breast cancer,[38] its opposite function can be observed in IDH1‐mutant glioma[7] and hsa_circ_0001546‐downregulated EOC, which means that genetic differences in various diseases should be considered in the clinical use of Tau inhibitors. This evidence concerns the gene IDH1 and Parkinson disease.